These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7266019)

  • 1. Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cell determined by flow cytometry.
    Sonneveld P; van den Engh GJ
    Leuk Res; 1981; 5(3):251-7. PubMed ID: 7266019
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells.
    Speth PA; Raijmakers RA; Boezeman JB; Linssen PC; de Witte TJ; Wessels HM; Haanen C
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):667-74. PubMed ID: 3383969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells.
    Seeber S; Loth H
    Blut; 1981 Jun; 42(6):355-65. PubMed ID: 6941824
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.
    Ganapathi R; Gulick P; Miller R; Grabowski D; Turinic R; Valeunzuela R; Fishleder A; Bukowski R
    Invest New Drugs; 1985; 3(3):273-7. PubMed ID: 3864764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the pharmacokinetics of daunomycin in normal and leukemic rats.
    Nooter K; Sonneveld P; Martens A
    Cancer Res; 1985 Sep; 45(9):4020-5. PubMed ID: 4027999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study.
    Chervinsky DS; Wang JJ
    J Med; 1976; 7(1):63-79. PubMed ID: 1064679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative evaluation of the myelotoxic action of rubomycin, adriamycin and carminomycin by their delayed effects in an experiment].
    Fursov SE; Novitskiĭ VV; Fedorenko EN; Gol'dberg ED
    Antibiot Med Biotekhnol; 1985 Apr; 30(4):284-8. PubMed ID: 4026249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells.
    Huybrechts M; Trouet A
    Cancer Chemother Pharmacol; 1980; 5(2):79-82. PubMed ID: 7471318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.
    Paul C; Peterson C; Gahrton G; Lockner D
    Cancer Chemother Pharmacol; 1979; 2(1):49-52. PubMed ID: 498420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative uptake of adriamycin and daunorubicin in sensitive and resistant friend leukemia cells measured by flow cytometry.
    Tapiero H; Fourcade A; Vaigot P; Farhi JJ
    Cytometry; 1982 Mar; 2(5):298-302. PubMed ID: 6951693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells.
    Nooter K; van den Engh G; Sonneveld P
    Cancer Res; 1983 Nov; 43(11):5126-30. PubMed ID: 6616450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.
    Smith MA; Merry S; Smith JG; Kaye SB
    Br J Cancer; 1988 Jun; 57(6):576-8. PubMed ID: 3408645
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence for the genotoxic effect of daunomycin in multipotent hematopoietic cells of mouse bone marrow: chromatin proteins analysis.
    Aramvash A; Rabbani-Chadegani A; Shahraki MK
    J Pharm Biomed Anal; 2012 Jul; 66():204-10. PubMed ID: 22445827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake of adriamycin by human leukemic cells as measured by flow cytometry.
    Preisler HD; Raza A
    Med Oncol Tumor Pharmacother; 1984; 1(1):43-8. PubMed ID: 6544358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation by flow cytometry of anthracycline drug uptake by peripheral blood and bone marrow cells in human leukemias.
    Sahar E; Michalevicz R; Broudo I; Seligsohn U
    Exp Hematol; 1986 Feb; 14(2):119-25. PubMed ID: 3455917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin.
    Minderman H; Linssen P; Wessels J; Haanen C
    Anticancer Res; 1993; 13(4):1161-5. PubMed ID: 8352539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity.
    Smeets M; Raymakers R; Vierwinden G; Pennings A; van de Locht L; Wessels H; Boezeman J; de Witte T
    Br J Haematol; 1997 Feb; 96(2):346-55. PubMed ID: 9029024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current model of hemopoiesis and possible targets of hemoblastosis].
    Vorob'ev AI; Brilliant MD; Chertkov IL
    Ter Arkh; 1981; 53(9):3-14. PubMed ID: 7302859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.